Cancer Immunotherapy-Europe Market Status and Trend Report 2013-2023
Report Summary
Cancer Immunotherapy-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Immunotherapy industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Cancer Immunotherapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Immunotherapy in Europe, with company and product introduction, position in the Cancer Immunotherapy market
Market status and development trend of Cancer Immunotherapy by types and applications
Cost and profit status of Cancer Immunotherapy, and marketing status
Market growth drivers and challenges
The report segments the Europe Cancer Immunotherapy market as:
Europe Cancer Immunotherapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Cancer Immunotherapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
Other
Europe Cancer Immunotherapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Europe Cancer Immunotherapy Market: Players Segment Analysis (Company and Product introduction, Cancer Immunotherapy Sales Volume, Revenue, Price and Gross Margin):
Amgen
AstraZeneca
F. Hoffman La-Roche
Bayer AG
Bristol-Myers Squibb
Eli Lilly and Company
Janssen Global Services
Merck
Novartis
Pfizer
Seattle Genetics
Peregrine Pharmaceuticals
Viralytics Ltd
Immunomedics
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Cancer Immunotherapy-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Immunotherapy industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Cancer Immunotherapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Immunotherapy in Europe, with company and product introduction, position in the Cancer Immunotherapy market
Market status and development trend of Cancer Immunotherapy by types and applications
Cost and profit status of Cancer Immunotherapy, and marketing status
Market growth drivers and challenges
The report segments the Europe Cancer Immunotherapy market as:
Europe Cancer Immunotherapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Cancer Immunotherapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
Other
Europe Cancer Immunotherapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Europe Cancer Immunotherapy Market: Players Segment Analysis (Company and Product introduction, Cancer Immunotherapy Sales Volume, Revenue, Price and Gross Margin):
Amgen
AstraZeneca
F. Hoffman La-Roche
Bayer AG
Bristol-Myers Squibb
Eli Lilly and Company
Janssen Global Services
Merck
Novartis
Pfizer
Seattle Genetics
Peregrine Pharmaceuticals
Viralytics Ltd
Immunomedics
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CANCER IMMUNOTHERAPY
1.1 Definition of Cancer Immunotherapy in This Report
1.2 Commercial Types of Cancer Immunotherapy
1.2.1 Melanoma
1.2.2 Colorectal cancer
1.2.3 Prostate cancer
1.2.4 Head and neck cancer
1.2.5 Breast cancer
1.2.6 Lung cancer
1.2.7 Other
1.3 Downstream Application of Cancer Immunotherapy
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Cancer Immunotherapy
1.5 Market Status and Trend of Cancer Immunotherapy 2013-2023
1.5.1 Europe Cancer Immunotherapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Immunotherapy Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Immunotherapy in Europe 2013-2017
2.2 Consumption Market of Cancer Immunotherapy in Europe by Regions
2.2.1 Consumption Volume of Cancer Immunotherapy in Europe by Regions
2.2.2 Revenue of Cancer Immunotherapy in Europe by Regions
2.3 Market Analysis of Cancer Immunotherapy in Europe by Regions
2.3.1 Market Analysis of Cancer Immunotherapy in Germany 2013-2017
2.3.2 Market Analysis of Cancer Immunotherapy in United Kingdom 2013-2017
2.3.3 Market Analysis of Cancer Immunotherapy in France 2013-2017
2.3.4 Market Analysis of Cancer Immunotherapy in Italy 2013-2017
2.3.5 Market Analysis of Cancer Immunotherapy in Spain 2013-2017
2.3.6 Market Analysis of Cancer Immunotherapy in Benelux 2013-2017
2.3.7 Market Analysis of Cancer Immunotherapy in Russia 2013-2017
2.4 Market Development Forecast of Cancer Immunotherapy in Europe 2018-2023
2.4.1 Market Development Forecast of Cancer Immunotherapy in Europe 2018-2023
2.4.2 Market Development Forecast of Cancer Immunotherapy by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Cancer Immunotherapy in Europe by Types
3.1.2 Revenue of Cancer Immunotherapy in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Cancer Immunotherapy in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Immunotherapy in Europe by Downstream Industry
4.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Immunotherapy by Downstream Industry in Germany
4.2.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Cancer Immunotherapy by Downstream Industry in France
4.2.4 Demand Volume of Cancer Immunotherapy by Downstream Industry in Italy
4.2.5 Demand Volume of Cancer Immunotherapy by Downstream Industry in Spain
4.2.6 Demand Volume of Cancer Immunotherapy by Downstream Industry in Benelux
4.2.7 Demand Volume of Cancer Immunotherapy by Downstream Industry in Russia
4.3 Market Forecast of Cancer Immunotherapy in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER IMMUNOTHERAPY
5.1 Europe Economy Situation and Trend Overview
5.2 Cancer Immunotherapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Cancer Immunotherapy in Europe by Major Players
6.2 Revenue of Cancer Immunotherapy in Europe by Major Players
6.3 Basic Information of Cancer Immunotherapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Immunotherapy Major Players
6.3.2 Employees and Revenue Level of Cancer Immunotherapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER IMMUNOTHERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Amgen
7.1.1 Company profile
7.1.2 Representative Cancer Immunotherapy Product
7.1.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Amgen
7.2 AstraZeneca
7.2.1 Company profile
7.2.2 Representative Cancer Immunotherapy Product
7.2.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of AstraZeneca
7.3 F. Hoffman La-Roche
7.3.1 Company profile
7.3.2 Representative Cancer Immunotherapy Product
7.3.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of F. Hoffman La-Roche
7.4 Bayer AG
7.4.1 Company profile
7.4.2 Representative Cancer Immunotherapy Product
7.4.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bayer AG
7.5 Bristol-Myers Squibb
7.5.1 Company profile
7.5.2 Representative Cancer Immunotherapy Product
7.5.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.6 Eli Lilly and Company
7.6.1 Company profile
7.6.2 Representative Cancer Immunotherapy Product
7.6.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.7 Janssen Global Services
7.7.1 Company profile
7.7.2 Representative Cancer Immunotherapy Product
7.7.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Janssen Global Services
7.8 Merck
7.8.1 Company profile
7.8.2 Representative Cancer Immunotherapy Product
7.8.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Merck
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Cancer Immunotherapy Product
7.9.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Novartis
7.10 Pfizer
7.10.1 Company profile
7.10.2 Representative Cancer Immunotherapy Product
7.10.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Pfizer
7.11 Seattle Genetics
7.11.1 Company profile
7.11.2 Representative Cancer Immunotherapy Product
7.11.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Seattle Genetics
7.12 Peregrine Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Cancer Immunotherapy Product
7.12.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Peregrine Pharmaceuticals
7.13 Viralytics Ltd
7.13.1 Company profile
7.13.2 Representative Cancer Immunotherapy Product
7.13.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Viralytics Ltd
7.14 Immunomedics
7.14.1 Company profile
7.14.2 Representative Cancer Immunotherapy Product
7.14.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Immunomedics
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER IMMUNOTHERAPY
8.1 Industry Chain of Cancer Immunotherapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER IMMUNOTHERAPY
9.1 Cost Structure Analysis of Cancer Immunotherapy
9.2 Raw Materials Cost Analysis of Cancer Immunotherapy
9.3 Labor Cost Analysis of Cancer Immunotherapy
9.4 Manufacturing Expenses Analysis of Cancer Immunotherapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER IMMUNOTHERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Cancer Immunotherapy in This Report
1.2 Commercial Types of Cancer Immunotherapy
1.2.1 Melanoma
1.2.2 Colorectal cancer
1.2.3 Prostate cancer
1.2.4 Head and neck cancer
1.2.5 Breast cancer
1.2.6 Lung cancer
1.2.7 Other
1.3 Downstream Application of Cancer Immunotherapy
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Cancer Immunotherapy
1.5 Market Status and Trend of Cancer Immunotherapy 2013-2023
1.5.1 Europe Cancer Immunotherapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Immunotherapy Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Immunotherapy in Europe 2013-2017
2.2 Consumption Market of Cancer Immunotherapy in Europe by Regions
2.2.1 Consumption Volume of Cancer Immunotherapy in Europe by Regions
2.2.2 Revenue of Cancer Immunotherapy in Europe by Regions
2.3 Market Analysis of Cancer Immunotherapy in Europe by Regions
2.3.1 Market Analysis of Cancer Immunotherapy in Germany 2013-2017
2.3.2 Market Analysis of Cancer Immunotherapy in United Kingdom 2013-2017
2.3.3 Market Analysis of Cancer Immunotherapy in France 2013-2017
2.3.4 Market Analysis of Cancer Immunotherapy in Italy 2013-2017
2.3.5 Market Analysis of Cancer Immunotherapy in Spain 2013-2017
2.3.6 Market Analysis of Cancer Immunotherapy in Benelux 2013-2017
2.3.7 Market Analysis of Cancer Immunotherapy in Russia 2013-2017
2.4 Market Development Forecast of Cancer Immunotherapy in Europe 2018-2023
2.4.1 Market Development Forecast of Cancer Immunotherapy in Europe 2018-2023
2.4.2 Market Development Forecast of Cancer Immunotherapy by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Cancer Immunotherapy in Europe by Types
3.1.2 Revenue of Cancer Immunotherapy in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Cancer Immunotherapy in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Immunotherapy in Europe by Downstream Industry
4.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Immunotherapy by Downstream Industry in Germany
4.2.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Cancer Immunotherapy by Downstream Industry in France
4.2.4 Demand Volume of Cancer Immunotherapy by Downstream Industry in Italy
4.2.5 Demand Volume of Cancer Immunotherapy by Downstream Industry in Spain
4.2.6 Demand Volume of Cancer Immunotherapy by Downstream Industry in Benelux
4.2.7 Demand Volume of Cancer Immunotherapy by Downstream Industry in Russia
4.3 Market Forecast of Cancer Immunotherapy in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER IMMUNOTHERAPY
5.1 Europe Economy Situation and Trend Overview
5.2 Cancer Immunotherapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Cancer Immunotherapy in Europe by Major Players
6.2 Revenue of Cancer Immunotherapy in Europe by Major Players
6.3 Basic Information of Cancer Immunotherapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Immunotherapy Major Players
6.3.2 Employees and Revenue Level of Cancer Immunotherapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER IMMUNOTHERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Amgen
7.1.1 Company profile
7.1.2 Representative Cancer Immunotherapy Product
7.1.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Amgen
7.2 AstraZeneca
7.2.1 Company profile
7.2.2 Representative Cancer Immunotherapy Product
7.2.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of AstraZeneca
7.3 F. Hoffman La-Roche
7.3.1 Company profile
7.3.2 Representative Cancer Immunotherapy Product
7.3.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of F. Hoffman La-Roche
7.4 Bayer AG
7.4.1 Company profile
7.4.2 Representative Cancer Immunotherapy Product
7.4.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bayer AG
7.5 Bristol-Myers Squibb
7.5.1 Company profile
7.5.2 Representative Cancer Immunotherapy Product
7.5.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.6 Eli Lilly and Company
7.6.1 Company profile
7.6.2 Representative Cancer Immunotherapy Product
7.6.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.7 Janssen Global Services
7.7.1 Company profile
7.7.2 Representative Cancer Immunotherapy Product
7.7.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Janssen Global Services
7.8 Merck
7.8.1 Company profile
7.8.2 Representative Cancer Immunotherapy Product
7.8.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Merck
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Cancer Immunotherapy Product
7.9.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Novartis
7.10 Pfizer
7.10.1 Company profile
7.10.2 Representative Cancer Immunotherapy Product
7.10.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Pfizer
7.11 Seattle Genetics
7.11.1 Company profile
7.11.2 Representative Cancer Immunotherapy Product
7.11.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Seattle Genetics
7.12 Peregrine Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Cancer Immunotherapy Product
7.12.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Peregrine Pharmaceuticals
7.13 Viralytics Ltd
7.13.1 Company profile
7.13.2 Representative Cancer Immunotherapy Product
7.13.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Viralytics Ltd
7.14 Immunomedics
7.14.1 Company profile
7.14.2 Representative Cancer Immunotherapy Product
7.14.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Immunomedics
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER IMMUNOTHERAPY
8.1 Industry Chain of Cancer Immunotherapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER IMMUNOTHERAPY
9.1 Cost Structure Analysis of Cancer Immunotherapy
9.2 Raw Materials Cost Analysis of Cancer Immunotherapy
9.3 Labor Cost Analysis of Cancer Immunotherapy
9.4 Manufacturing Expenses Analysis of Cancer Immunotherapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER IMMUNOTHERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
